Tekmira Legacy Drug Launched in US by Licensee Spectrum | GenomeWeb

Tekmira Pharmaceuticals this week announced that Spectrum Pharmaceuticals, which licensed Tekmira's non-RNAi cancer drug Marqibo earlier this year, has launched the product in the US.

The drug is a version of the approved chemotherapeutic vincristine formulated with Tekmira's liposome technology. It is a legacy product developed by Tekmira prior to its becoming a pure-play RNAi drug developer, and was later licensed to Talon Therapeutics. Talon was acquired by Spectrum in July.

Tekmira stands to receive royalties on sales of Marqibo.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.